Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants

22 Aug 2023

Abstract excerpt

Coronaviruses have been the causative agent of three epidemics and pandemics in the past two decades, including the ongoing COVID-19 pandemic. A broadly-neutralizing coronavirus therapeutic is desirable not only to prevent and treat COVID-19, but also to provide protection for high-risk populations against future emergent coronaviruses. As all coronaviruses use spike proteins on the viral surface to enter the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37608223
DOI: 10.1038/s41598-023-40919-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variantsPMID 37608223Read ↗

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spikeSemantic proximity Read ↗

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 VariantsSemantic proximity Read ↗

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read ↗

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read ↗

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its baseSemantic proximity Read ↗

Broadly neutralizing antibodies against COVID-19Semantic proximity Read ↗

Design of SARS-CoV-2 RBD Immunogens to Focus Immune Responses Towards Conserved Coronavirus EpitopesSemantic proximity Read ↗

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralizationSemantic proximity Read ↗

Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopesSemantic proximity Read ↗

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognitionSemantic proximity Read ↗

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikeSemantic proximity Read ↗

Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.